Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+ (Journal of Thoracic Oncology, 2018)

(untitled) - Talbot, D; Govindan, R; Cobo, M; Ponce Aix, S; Postmus, PE; Lewanski, C; Bennouna, J; Fischer, J; Juan-Vidal, O; Stewart, D; Ardizzoni, A; Bhore, R; et al.